MCID: ORL015
MIFTS: 43

Oral Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Oral Squamous Cell Carcinoma

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 12 74 20 15 17
Squamous Cell Carcinoma of Mouth 71
Mouth Squamous Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050866
UMLS 71 C0585362

Summaries for Oral Squamous Cell Carcinoma

Disease Ontology : 12 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary : Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and tongue squamous cell carcinoma. An important gene associated with Oral Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Melatonin and Protective Agents have been mentioned in the context of this disorder. Affiliated tissues include lymph node, tongue and bone.

Wikipedia : 74 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Related Diseases for Oral Squamous Cell Carcinoma

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.5 UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
2 tongue squamous cell carcinoma 32.0 UCA1 MIR21 MEG3 MALAT1
3 b-cell lymphoma 31.6 TUG1 MIR21 MALAT1 HOTAIR
4 glioblastoma 31.5 TUG1 MIR21 MIR137 MEG3 MALAT1 HOTAIR
5 lung cancer susceptibility 3 31.5 TUG1 MIR21 MEG3 MALAT1 HOTAIR H19
6 melanoma 31.5 UCA1 MIR193A MIR137 MIR100 MEG3 MALAT1
7 esophageal cancer 31.4 UCA1 MIR21 MIR193A MIR100 MEG3 MALAT1
8 nasopharyngeal carcinoma 31.1 NEAT1 MIR21 MIR100 MEG3 MALAT1 HOTAIR
9 bladder cancer 31.1 UCA1 TUG1 MIR21 MIR193A MIR100 MEG3
10 retinitis pigmentosa 11 31.1 UCA1 TUG1 NEAT1 HOTAIR
11 pancreatic ductal adenocarcinoma 31.0 UCA1 MIR21 MALAT1 HOTAIR H19
12 leukemia, acute myeloid 31.0 UCA1 TUG1 MIR21 MIR193A MEG3 MALAT1
13 osteogenic sarcoma 31.0 UCA1 TUG1 NEAT1 MEG3 MALAT1 HOTAIR
14 lung cancer 30.9 UCA1 TUG1 NEAT1 MIR21 MIR193A MIR137
15 myeloma, multiple 30.8 UCA1 TUG1 MIR21 MEG3 MALAT1 HOTAIR
16 kidney cancer 30.8 MIR21 MEG3 MALAT1 HOTAIR H19
17 thyroid cancer, nonmedullary, 1 30.8 NEAT1 MEG3 MALAT1 HOTAIR H19
18 thyroid carcinoma 30.7 UCA1 NEAT1 MALAT1 HOTAIR H19
19 cervical cancer 30.7 UCA1 TUG1 NEAT1 MIR21 MEG3 MALAT1
20 renal cell carcinoma, nonpapillary 30.7 UCA1 TUG1 MIR21 MIR193A MALAT1 HOTAIR
21 endometrial cancer 30.7 UCA1 TUG1 NEAT1 MEG3 HOTAIR H19
22 pre-eclampsia 30.6 TUG1 MALAT1 HOTAIR H19
23 ovarian cancer 30.5 UCA1 TUG1 NEAT1 MIR21 MIR193A MIR100
24 oral cancer 11.5
25 leukoplakia 11.1
26 oral leukoplakia 11.0
27 lichen planus 10.9
28 oral lichen planus 10.9
29 oral submucous fibrosis 10.9
30 papilloma 10.8
31 squamous cell papilloma 10.8
32 tongue carcinoma 10.8
33 in situ carcinoma 10.8
34 fibrosis of extraocular muscles, congenital, 1 10.8
35 hypoxia 10.7
36 mucositis 10.7
37 oral cavity cancer 10.7
38 verrucous carcinoma 10.7
39 severe combined immunodeficiency 10.6
40 keratosis 10.6
41 oculopharyngeal muscular dystrophy 10.6
42 hypereosinophilic syndrome 10.6
43 bone resorption disease 10.6
44 oral mucosa leukoplakia 10.6
45 gallbladder cancer 10.6 UCA1 TUG1 MEG3 MALAT1 HOTAIR H19
46 small cell cancer of the lung 10.6 TUG1 MIR21 MALAT1 HOTAIR CCAT2
47 esophagus squamous cell carcinoma 10.6 TUG1 MEG3 HOTAIR
48 familial adenomatous polyposis 10.6
49 neutropenia 10.6
50 periodontitis 10.6

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
2 Protective Agents Phase 3
3 Antioxidants Phase 3
4
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
5 Raspberry Approved Phase 1, Phase 2
6
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
7
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
8
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
9
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
10
Fluorouracil Approved Phase 2 51-21-8 3385
11
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
12
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
13
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
14 Antineoplastic Agents, Immunological Phase 2
15 Albumin-Bound Paclitaxel Phase 2
16 Pharmaceutical Solutions Phase 1, Phase 2
17 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
18 Immunoglobulins Phase 2
19 Antibodies Phase 2
20 Antibodies, Monoclonal Phase 2
21 Anti-Inflammatory Agents Phase 2
22 Analgesics, Non-Narcotic Phase 2
23 Cyclooxygenase Inhibitors Phase 2
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2
25 Cyclooxygenase 2 Inhibitors Phase 2
26 Antirheumatic Agents Phase 2
27 Analgesics Phase 2
28
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
29 Mitogens Phase 2
30 Protein Kinase Inhibitors Phase 2
31 Antimitotic Agents Phase 2
32 Tubulin Modulators Phase 2
33 Immunosuppressive Agents Phase 2
34 Immunologic Factors Phase 2
35 Antimetabolites Phase 2
36
Apatinib Phase 1 811803-05-1
37
carbamide peroxide Approved 124-43-6
38
Phenol Approved, Experimental Early Phase 1 108-95-2 996
39
Licorice Approved Early Phase 1
40 Antiviral Agents Early Phase 1
41 Antimalarials Early Phase 1
42 Anti-Bacterial Agents Early Phase 1
43 Omega 3 Fatty Acid
44 Tolonium Chloride
45 Anti-Infective Agents
46 Complement System Proteins
47
Arginine Investigational, Nutraceutical 74-79-3 6322

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
2 Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT04137627 Phase 3 Melatonin 20 MG Oral Capsule;Placebo oral capsule
3 Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
4 Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer Unknown status NCT02739204 Phase 2 Celecoxib
5 A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
6 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
7 A Phase II, Prospective, Single-center, Randomized, Controlled Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma Recruiting NCT04367909 Phase 2 Nimotuzumab;Docetaxel;Carboplatin
8 Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma Recruiting NCT03502148 Phase 1, Phase 2 PRV111 (Cisplatin Transmucosal System)
9 A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
10 Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity Squamous Cell Carcinoma . Recruiting NCT04718415 Phase 2 sintilimab, paclitaxel, carboplatin
11 A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma Recruiting NCT02285543 Phase 2 TPF induction chemotherapy
12 GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial Recruiting NCT02285530 Phase 2 TPF induction chemotherapy
13 Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial Recruiting NCT02290145 Phase 2 TPF group
14 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
15 A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma Not yet recruiting NCT04649476 Phase 2 Camrelizumab;Camrelizumanb plus TPF
16 Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma Completed NCT00009841 Phase 1 DC-cholesterol liposome
17 Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC): A Phase I Trial Recruiting NCT04413214 Phase 1 Carrimycin
18 Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial Recruiting NCT04473716 Phase 1 Toripalimab;Paclitaxcel;Cisplatin
19 Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial Recruiting NCT04393506 Phase 1 Camrelizumab;Apatinib
20 Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma Unknown status NCT01987934
21 Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line Unknown status NCT03619304
22 Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma Unknown status NCT01587573
23 Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study Unknown status NCT03345966
24 SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck Unknown status NCT00571883
25 The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Unknown status NCT00173849
26 Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line Unknown status NCT03292822 Early Phase 1 Paclitaxel
27 The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Unknown status NCT01946230
28 The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Unknown status NCT02009852
29 A Cohort Study on Prediction of Malignant Transformation of Oral Epithelial Dysplasia by p16 Methylation Completed NCT00835341
30 A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma Completed NCT01465776
31 A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer Completed NCT01314755
32 Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma Completed NCT03554967
33 Fluorescent Visualization in Early Oral Cancer Completed NCT02306967
34 Etude de Concordance Entre la Technique OSNA et Les Techniques Classiques Pour la Recherche de métastases Ganglionnaires Des Cancers Des VADS Completed NCT02852343
35 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
36 Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma. Completed NCT02323672
37 Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study) Completed NCT03109457
38 Modern Hybrid Imaging for Staging and Monitoring Patients With Oral Squamous Cell Carcinoma Completed NCT04280159
39 Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma-A Prospective Multicenter Randomized Controlled Study Recruiting NCT01334320
40 Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions Recruiting NCT04188665 Early Phase 1 MASL
41 Prospective Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore Recruiting NCT03975322
42 A Randomized,Multicenter,Prospectie,Controlled Clinical Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma. Recruiting NCT02743832
43 Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning Recruiting NCT04543266
44 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
45 Submandibular Gland Preservation During Neck Dissection for Oral Squamous Cell Carcinoma Recruiting NCT03385720
46 Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma Recruiting NCT03877159
47 A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer. Active, not recruiting NCT01772706
48 Myeloid-derived Suppressor Cells (MDSCs) Detection Before and After Beta-glucan Administration in Oral Squamous Cell Carcinoma Patients Active, not recruiting NCT04387682
49 Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population Not yet recruiting NCT04270201
50 International, Multicenter, Prospective Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction (SMDR) Following Oral Squamous Cell Carcinoma (OSSC) Resection Not yet recruiting NCT04098146

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

Anatomical Context for Oral Squamous Cell Carcinoma

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

40
Lymph Node, Tongue, Bone, Endothelial, T Cells, Neutrophil, Myeloid

Publications for Oral Squamous Cell Carcinoma

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 10259)
# Title Authors PMID Year
1
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. 47 61
19396866 2009
2
The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. 47 61
19435529 2009
3
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. 61 47
18381414 2008
4
Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. 47
18946016 2008
5
Peroxidase-mimicking evodiamine/indocyanine green nanoliposomes for multimodal imaging-guided theranostics for oral squamous cell carcinoma. 61
33511313 2021
6
Body mass index and self-care behaviors related to oral health-related quality of life in patients with oral squamous cell carcinoma within three months posttreatment. 61
32910290 2021
7
Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities. 61
33091960 2021
8
Oral and general health-related quality of life in oral squamous cell carcinoma patients- comparative analysis of different treatment regims. 61
33532199 2021
9
Volume-regulated chloride channel regulates cell proliferation and is involved in the possible interaction between TMEM16A and LRRC8A in human metastatic oral squamous cell carcinoma cells. 61
33476655 2021
10
Bioinformatics and immunohistochemistry analyses of expression levels and clinical significance of CXCL2 and TANs in an oral squamous cell carcinoma tumor microenvironment of Prophyromonas gingivalis infection. 61
33574928 2021
11
Oral Squamous Cell Carcinoma in a 5-Year-Old Patient: A Rare Clinical Entity and Literature Review. 61
33584041 2021
12
The Gain-of-Function Mutation p53R248W Suppresses Cell Proliferation and Invasion of Oral Squamous Cell Carcinoma through the Down-Regulation of Keratin 17. 61
33307039 2021
13
Patterns of oral mucositis in advanced oral squamous cell carcinoma patients managed with prophylactic photobiomodulation therapy-insights for future protocol development. 61
32627112 2021
14
Staging more important than grading? Evaluation of malignancy grading, depth of invasion, and resection margins in oral squamous cell carcinoma. 61
32601998 2021
15
Salivary CCL20 Level as a Biomarker for Oral Squamous Cell Carcinoma. 61
33608307 2021
16
DNA repair, NFKβ, and TP53 polymorphisms associated with potentially malignant disorders and oral squamous cell carcinoma in Argentine patients. 61
33309268 2021
17
Impact of lymphovascular invasion in oral squamous cell carcinoma: A meta-analysis. 61
33309267 2021
18
Is Salivary Sialic Acid a Reliable Biomarker in the Detection of Oral Potentially Malignant Disorder and Oral Squamous Cell Carcinoma. 61
33584047 2021
19
Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor-κB-dependent pathway. 61
33500696 2021
20
MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma. 61
33398370 2021
21
circPHIP promotes oral squamous cell carcinoma progression by sponging miR-142-5p and regulating PHIP and ACTN4 expression. 61
33376626 2021
22
The novel therapeutic potential of bovine α-lactalbumin made lethal to tumour cells (BALMET) and oleic acid in oral squamous cell carcinoma (OSCC). 61
32694279 2021
23
Overexpression of RRM2 is related to poor prognosis in oral squamous cell carcinoma. 61
32640108 2021
24
High-risk human papillomavirus in patients with oral leukoplakia and oral squamous cell carcinoma-A multi-centre study in Sweden, Brazil and Romania. 61
32568421 2021
25
Dietary fat and male sex increase histopathological changes in a mouse model of oral cancer. 61
32640482 2021
26
Isorhamnetin induces the paraptotic cell death through ROS and the ERK/MAPK pathway in OSCC cells. 61
32654232 2021
27
Function of gold nanoparticles in oral cancer beyond drug delivery: Implications in cell apoptosis. 61
32657515 2021
28
Identification of potential glycoprotein biomarkers in oral squamous cell carcinoma using sweet strategies. 61
33547992 2021
29
Assessment of serum synuclein-γ and squamous cell carcinoma antigen as diagnostic biomarkers in patients with oral squamous cell carcinoma and oral potentially malignant disorders. 61
33064859 2021
30
Exosome-derived long non-coding RNA ADAMTS9-AS2 suppresses progression of oral submucous fibrosis via AKT signalling pathway. 61
33345447 2021
31
The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation-An Immunohistochemical Study. 61
33544386 2021
32
Diagnostic yield of sentinel lymph node biopsy in oral squamous cell carcinoma T1/T2-N0: systematic review and meta-analysis. 61
33602650 2021
33
Assessing skeletal muscle mass based on the cross-sectional area of muscles at the 12th thoracic vertebra level on computed tomography in patients with oral squamous cell carcinoma. 61
33388617 2021
34
TGF-β1 induces amoeboid-to-mesenchymal transition of CD44high oral squamous cell carcinoma cells via miR-422a downregulation through ERK activation and Cofilin-1 phosphorylation. 61
33107637 2021
35
MMP1 3'UTR facilitates the proliferation and migration of human oral squamous cell carcinoma by sponging miR-188-5p to up-regulate SOX4 and CDK4. 61
33090337 2021
36
Oral squamous cell carcinoma may originate from bone marrow-derived stem cells. 61
33552287 2021
37
Activation of EGFR-Aurora A induces loss of primary cilia in oral squamous cell carcinoma. 61
33529425 2021
38
The impact of close surgical margins on recurrence in oral squamous cell carcinoma. 61
33579388 2021
39
Aberrant promoter methylation of T-cadherin in sera is associated with a poor prognosis in oral squamous cell carcinoma. 61
33567853 2021
40
Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab. 61
33561855 2021
41
hsa_circ_0072387 Suppresses Proliferation, Metastasis, and Glycolysis of Oral Squamous Cell Carcinoma Cells by Downregulating miR-503-5p. 61
32302508 2021
42
Screening and validation of plasma long non-coding RNAs as biomarkers for the early diagnosis and staging of oral squamous cell carcinoma. 61
33552289 2021
43
[Advances in Hippo signaling pathway in oral squamous cell carcinoma]. 61
33557511 2021
44
Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma. 61
33546637 2021
45
Knockdown of Metadherin suppressed the progression of oral squamous cell carcinoma via PI3K/AKT signaling pathway. 61
33565287 2021
46
Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors. 61
33594603 2021
47
LncRNA LINC00974 Downregulates miR-122 to Upregulate RhoA in Oral Squamous Cell Carcinoma. 61
31702382 2021
48
Suppression of miR-886-3p mediated by arecoline (ARE) contributes to the progression of oral squamous cell carcinoma. 61
33310761 2021
49
Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma. 61
33029887 2021
50
microRNA-133a exerts tumor suppressive role in oral squamous cell carcinoma through the Notch signaling pathway via downregulation of CTBP2. 61
33531645 2021

Variations for Oral Squamous Cell Carcinoma

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 164)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 57445 11 63400000 77100000 Amplification CCND1 Oral squamous cell carcinoma
6 57446 11 63400000 77100000 Amplification CTTN Oral squamous cell carcinoma
7 57448 11 63400000 77100000 Amplification FGF3 Oral squamous cell carcinoma
8 57449 11 63400000 77100000 Amplification FGF4 Oral squamous cell carcinoma
9 57450 11 63400000 77100000 Amplification PPP1CA Oral squamous cell carcinoma
10 57451 11 63400000 77100000 Amplification LTO1 Oral squamous cell carcinoma
11 58782 11 69471367 69490165 Amplification LTO1 Oral squamous cell carcinoma
12 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
13 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
14 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
15 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
16 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
17 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
18 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
19 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
20 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
21 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
22 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
23 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
24 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
25 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
26 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
27 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
28 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
29 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
30 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
31 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
32 86340 14 58100000 67900000 Deletion Oral squamous cell carcinoma
33 86341 14 58100000 73800000 Deletion Oral squamous cell carcinoma
34 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
35 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
36 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
37 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
38 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
39 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
40 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
41 93371 15 52900000 72700000 Deletion Oral squamous cell carcinoma
42 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
43 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
44 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
45 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
46 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
47 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
48 109058 17 24000000 81195210 Noncopy numberrandom LOH Oral squamous cell carcinoma
49 112186 17 38100000 57600000 Deletion Oral squamous cell carcinoma
50 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma

Expression for Oral Squamous Cell Carcinoma

Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for Oral Squamous Cell Carcinoma

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.88 UCA1 MEG3 HOTAIR

GO Terms for Oral Squamous Cell Carcinoma

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 8.8 MIR21 MIR193A MIR100

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.43 MIR21 MIR193A MIR137
2 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.37 MIR21 H19
3 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.33 MIR21 MIR193A MIR137
4 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.32 MIR21 MIR137
5 gene silencing by miRNA GO:0035195 9.17 NEAT1 MIR21 MIR193A MIR137 MIR100 MEG3
6 negative regulation of superoxide dismutase activity GO:1901670 8.96 MIR21 H19

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR21 MIR193A MIR137 MIR100

Sources for Oral Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....